咨询与建议

限定检索结果

文献类型

  • 91 篇 期刊文献

馆藏范围

  • 91 篇 电子文献
  • 0 种 纸本馆藏

日期分布

学科分类号

  • 80 篇 医学
    • 69 篇 临床医学
    • 66 篇 基础医学(可授医学...
    • 4 篇 中西医结合
    • 1 篇 药学(可授医学、理...
  • 13 篇 理学
    • 8 篇 生物学
    • 1 篇 化学
  • 7 篇 工学
    • 2 篇 生物医学工程(可授...
    • 1 篇 生物工程
  • 2 篇 农学
    • 2 篇 作物学

主题

  • 2 篇 breast cancer
  • 2 篇 mechanisms of di...
  • 1 篇 regional
  • 1 篇 NOT FOUND
  • 1 篇 jq1
  • 1 篇 tmz, temozolomid...
  • 1 篇 NOT FOUND
  • 1 篇 cdk2
  • 1 篇 rash
  • 1 篇 NOT FOUND
  • 1 篇 NOT FOUND
  • 1 篇 tumor immunity
  • 1 篇 bladder cancer
  • 1 篇 NOT FOUND
  • 1 篇 NOT FOUND
  • 1 篇 cyclin dependent...
  • 1 篇 dasatinib
  • 1 篇 NOT FOUND
  • 1 篇 myeloproliferati...
  • 1 篇 nf-κb

机构

  • 43 篇 human oncology a...
  • 19 篇 leukemia service...
  • 15 篇 memorial sloan k...
  • 14 篇 department of me...
  • 14 篇 center for hemat...
  • 11 篇 human oncology a...
  • 10 篇 department of me...
  • 10 篇 leukemia service...
  • 10 篇 department of pa...
  • 10 篇 leukemia service...
  • 8 篇 memorial sloan-k...
  • 7 篇 human oncology a...
  • 7 篇 foundation medic...
  • 7 篇 center for epige...
  • 6 篇 human oncology a...
  • 6 篇 memorial sloan k...
  • 5 篇 department of ep...
  • 5 篇 department of bi...
  • 4 篇 division of hema...
  • 4 篇 lymphoma service...

作者

  • 37 篇 levine ross l.
  • 20 篇 abdel-wahab omar
  • 16 篇 rampal raajit k.
  • 10 篇 tallman martin s...
  • 7 篇 patel minal
  • 7 篇 chung young rock
  • 6 篇 lipson doron
  • 6 篇 dogan ahmet
  • 6 篇 stephens philip ...
  • 6 篇 miller vincent a...
  • 6 篇 stein eytan m.
  • 6 篇 durham benjamin ...
  • 5 篇 taylor justin
  • 5 篇 chung stephen s.
  • 5 篇 otto geoff a.
  • 5 篇 nahas michelle k...
  • 5 篇 devlin sean m.
  • 5 篇 omar abdel-wahab
  • 5 篇 park jae h.
  • 5 篇 famulare christo...

语言

  • 91 篇 英文
检索条件"机构=Leukemia Service and Human Oncology and Pathogenesis Program"
91 条 记 录,以下是1-10 订阅
排序:
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
收藏 引用
Blood 2025年 第18期145卷 2056-2069页
作者: Galera, Pallavi Dilip, Deepika Derkach, Andriy Chan, Alexander Zhang, Yanming Persaud, Sonali Mishra, Tanmay Kramer, Kyle Kathpalia, Mahak Liu, Ying Famulare, Christopher Gao, Qi Mata, Douglas A. Arcila, Maria Geyer, Mark B. Stein, Eytan Dogan, Ahmet Roshal, Mikhail Levine, Ross L. Glass, Jacob Xiao, Wenbin Hematopathology Service Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY United States Center for Epigenetics Research Memorial Sloan Kettering Cancer Center New York NY United States Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York NY United States Department of Pathology and Laboratory Medicine Cytogenetics Laboratory Memorial Sloan Kettering Cancer Center New York NY United States Molecular Cancer Medicine Service Human Oncogenesis and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY United States Department of Pathology and Laboratory Medicine Diagnostic Molecular Laboratory Memorial Sloan Kettering Cancer Center New York NY United States Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York NY United States Leukemia Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY United States Cell Therapy Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY United States
A mixed phenotype (MP) is a characteristic of de novo MP acute leukemia (MPAL), but it can also be found in other leukemias. It poses substantial classification and management dilemmas. Herein, we report a large cohor...
来源: 评论
SETD2-linking stem cell survival and transformation
收藏 引用
细胞研究(英文版) 2018年 第4期28卷 393-394页
作者: Mrinai M. Patnaik Omar Abdel-Wahab Department of Internal Medicine Mayo Clinic Division of Hematology Rochester MN USA Human Oncology and Pathogenesis Program and Acute Leukemia Service Memorial Sloan Kettering Cancer Center New York NY 10065 USA
SETD2 encodes a histone H3 lysine 36 (H3K36) methyltrans-ferase affected by mutations and deletions in a wide variety of cancers. Whether SETD2 loss alone can initiate tumorigenesis has not been established previously... 详细信息
来源: 评论
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid oncology Group statement
收藏 引用
The Lancet Diabetes and Endocrinology 2025年 第6期13卷 516-527页
作者: Leboulleux, Sophie Boucai, Laura Busaidy, Naifa Durante, Cosimo Fagin, James A Fazeli, Sasan Gianoukakis, Andrew G Haugen, Bryan R Kang, Hyunseok Konda, Bhavana Laetsch, Theodore W Locati, Laura Ryder, Mabel Spitzweg, Christine Worden, Francis P Wirth, Lori Ho, Alan Department of Medicine Endocrinology and Diabetology Service Geneva University Hospitals and Univerisity of Geneva Geneva Switzerland Department of Medicine Endocrinology Service Memorial Sloan Kettering Cancer Center New York NY United States Department of Endocrine Neoplasia and Hormonal Disorders The University of Texas MD Anderson Cancer Center Houston TX United States Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy Department of Medicine Memorial Sloan Kettering Cancer Center New York NY United States Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY United States Department of Clinical Diabetes Endocrinology & Metabolism City of Hope Comprehensive Cancer Center Duarte CA United States Division of Endocrinology Diabetes and Metabolism David Geffen School of Medicine at UCLA Harbor-UCLA Medical Center Los Angeles CA United States Division of Endocrinology Metabolism and Diabetes University of Colorado School of Medicine Aurora CO United States Department of Medicine University of California at San Francisco San Francisco CA United States Division of Medical Oncology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus OH United States Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia PA United States Medical Oncology Unit Istituti Clinici Scientifici Maugeri IRCCS Pavia Italy Division of Endocrinology Diabetes Metabolism and Nutrition Mayo Clinic Rochester MN United States Department of Internal Medicine IV LMU Munich Germany Division of Endocrinology Diabetes Metabolism and Nutrition Mayo Clinic Rochester Minnesota United States Department of Internal Medicine Division of Hematology and Oncology University of Michigan Rogel Cancer Center Ann Arbor MI United States Harvard Medical School Boston MA United States Center for Head and Neck Cancers Massachusetts General Hospital
In patients with follicular cell-derived thyroid cancer that have distant metastases and no iodine uptake, redifferentiation—ie, the restoration of tumoural 131I uptake with systemic therapy—is now possible. The use...
来源: 评论
LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation
收藏 引用
BLOOD 2020年 136卷 50-51页
作者: Rampal, Raajit K. McGrath, John P. Krishnan, Aishwarya Li, Bing Xiao, Wenbin Nikom, David Wang, Jing Levine, Ross L. Trojer, Patrick Leukemia Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY Translational Sciences Constellation Pharmaceuticals Cambridge MA Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York NY Department of Pathology Memorial Sloan Kettering Cancer Center New York NY Constellation Pharmaceuticals Cambridge MA Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center New York NY
Several novel mechanism-based therapeutic modalities are currently being clinically investigated for the treatment of patients with acute myelogenous leukemia (AML), including agents that exploit genomic vulnerabiliti...
来源: 评论
Treatment breakthroughs for the management of acute myeloid leukemia
收藏 引用
International Journal of Hematologic oncology 2012年 第2期1卷 121-132页
作者: Justin M Watts Ross L Levine Martin S Tallman Leukemia Service Department of Medicine Memorial Sloan–Kettering Cancer Center New York NY USA Human Oncology & Pathogenesis Program Leukemia Service Department of Medicine Memorial Sloan–Kettering Cancer Center New York NY USA Leukemia Service Department of Medicine Memorial Sloan–Kettering Cancer Center New York NY USA.
SUMMARY Although there has been substantial improvement in the survival of younger patients with acute myeloid leukemia (AML) since the 1970s, over the past two decades subsequent gains have been modest. Survival rate...
来源: 评论
Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
收藏 引用
BLOOD 2020年 136卷 47-48页
作者: Stahl, Maximilian Menghrajani, Kamal Derkach, Andriy Chan, Alexander Xiao, Wenbin Glass, Jacob L. King, Amber C. Daniyan, Anthony Famulare, Christopher Cuello, Bernadette M. Abdel-Wahab, Omar Levine, Ross L. Viny, Aaron D. Stein, Eytan M. Roshal, Mikhail Tallman, Martin S. Goldberg, Aaron D. Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center New York NY Weill Cornell Medical College New York NY Department of Biostatistics and Epidemiology Memorial Sloan Kettering Cancer Center New York NY Department of Pathology Memorial Sloan Kettering Cancer Center New York NY Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York Center for Epigenetics Research Memorial Sloan Kettering Cancer Center New York NY Department of Pharmacy Memorial Sloan Kettering Cancer Center New York NY Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center NY NY Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York NY Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY Memorial Sloan-Kettering Cancer Center New York NY Department of Medicine Leukemia Service Memorial Sloan-Kettering Cancer Center New York NY
Background: Venetoclax combined with azacitidine (aza/ven), decitabine (dec/ven), and low-dose cytarabine (LDAC/ven) is commonly used off-label in relapsed/refractory (RR)-AML patients; however, predictors of response...
来源: 评论
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives (vol 21, pg 185, 2024)
收藏 引用
NATURE REVIEWS CLINICAL oncology 2024年 第9期21卷 701-701页
作者: Marra, Antonio Chandarlapaty, Sarat Modi, Shanu Division of New Drugs and Early Drug Development European Institute of Oncology IRCCS Milan Italy Human Oncology and Pathogenesis Program (HOPP) Memorial Sloan Kettering Cancer Center New York NY USA Breast Medicine Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA Weill Cornell Medical College New York NY USA
Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes. Relentless research e... 详细信息
来源: 评论
BRAFV600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell leukemia
收藏 引用
BLOOD 2013年 第21期122卷 816-816页
作者: Chung, Stephen S. Park, Jae H. Kim, Eunhee Chung, Young Rock Hu, Wenhuo Lito, Piro Feldstein, Julie Teruya Rampal, Raajit K. Telis, Leon Patel, Minal Rosen, Neal Park, Christopher Y. Tallman, Martin S. Abdel-Wahab, Omar Leukemia Service Department of Medicine Memorial Sloan-Kettering Cancer Center New York NY USA Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center New York NY USA Leukemia Service and Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center New York City NY USA Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY USA Pharmacology Memorial Sloan-Kettering Cancer Center New York USA Department of Pathology Memorial Sloan-Kettering Cancer Center New York NY USA Human Oncology and Pathogenesis Program and Leukemia Service Memorial Sloan-Kettering Cancer Center New York NY USA Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center New York USA Medicine Memorial Sloan-Kettering Cancer Center New York USA Pathology and Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center New York NY USA
816
来源: 评论
Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay
收藏 引用
BLOOD 2013年 第21期122卷 230-230页
作者: Lipson, Doron Nahas, Michelle K. Otto, Geoff A. Yelensky, Roman Abdel-Wahab, Omar Wang, Kai He, Jie Intlekofer, Andrew M. Rampal, Raajit K. Brennan, Timothy A. Knapp, Kristina M. Brennan, Kristina W. Young, Geneva Donahue, Amy L. Sanford, Eric M. Greenbowe, Joel R. Frampton, Garrett M. Fichtenholtz, Alex Young, Lauren E. Erlich, Rachel L. Parker, Alex Klimstra, David Dogan, Ahmet Ross, Jeffrey S. Armstrong, Scott A. Stephens, Philip J. van den Brink, Marcel R. M. Miller, Vincent A. Levine, Ross L. Foundation Medicine Inc Cambridge MA USA Leukemia Service and Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center New York City NY USA Department of Medicine Memorial Sloan-Kettering Cancer Center New York NY USA Human Oncology and Pathogenesis Program and Leukemia Service Memorial Sloan-Kettering Cancer Center New York NY USA
230
来源: 评论
ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1
收藏 引用
BLOOD 2020年 136卷 10-11页
作者: Inoue, Daichi Polaski, Jacob T. Taylor, Justin Castel, Pau Chen, Sisi Kobayashi, Susumu Hogg, Simon J. Hayashi, Yasutaka Pineda, Jose Mario Bello Penson, Alexander V. El Marabti, Ettaib Erickson, Caroline Fukumoto, Miki Yamazaki, Hiromi Fukui, Chie Lu, Sydney X. Durham, Benjamin H. Liu, Bo Mehta, Sanjoy Zakheim, Daniel Garippa, Ralph Chew, Guo-Liang McCormick, Frank Bradley, Robert K. Abdel-Wahab, Omar Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY Department of Hematology-Oncology Institute of Biomedical Research and Innovation Foundation for Biomedical Research and Innovation at Kobe Kobe Japan Public Health Sciences and Basic Sciences Divisions Fred Hutchinson Cancer Research Center Seattle Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center Miami FL Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco Foundation for Biomedical Research and Innovation at Kobe Kobe Japan Department of Genome Sciences University of Washington Seattle Memorial Sloan Kettering Cancer Center New York Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York Myeloma Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY Gene Editing & Screening Facility Memorial Sloan Kettering Cancer Center New York
Mutations in RNA splicing factors are amongst the most common genetic alterations in myeloid malignancies. Mutations in the splicing factors SF3B1 , SRSF2 , and U2AF1 occur as heterozygous, missense mutations and have...
来源: 评论